#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dementia Alzheimer's type Dermatitis atopic Asthma Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Central nervous system neoplasm Cushing's syndrome Pericarditis Arterial disorder Chronic lymphocytic leukaemia recurrent HER2 mutant non-small cell lung cancer Immune thrombocytopenia Cerebellar ataxia Adrenoleukodystrophy High-grade B-cell lymphoma Small cell lung cancer extensive stage Choroidal dystrophy Erythema Becker's muscular dystrophy Thrombocytosis More trials…

    Learn about Rare Diseases

    Mucopolysaccharidosis III – Basic Information Castleman’s disease – Trials in Disease Alagille syndrome – Trials in Disease Haemolytic uraemic syndrome – Basic Information Angiosarcoma – Life with Disease Ewing’s sarcoma recurrent – Trials in Disease Congenital nephrogenic diabetes insipidus – Life with Disease Vascular malformation Lysosomal storage disorder – Life with Disease Alport’s syndrome More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Naloxone M2Rlab Retinol Acetate Remimazolam Fulvestrant Sodium Hyaluronate Glycine Tin816 Regtivex Fedratinib Methoxyflurane Efpegerglucagon Sulfonamides, Urea Derivatives Idursulfase Alrefimotide Orlistat ORX750 Tumor Necrosis Factor-Alpha Oritavancin Ibutamoren Mesilate More therapies…

    Learn about Your Condition

    Subarachnoid haemorrhage Phenylketonuria Lymphoma Cerebral palsy Acute myocardial infarction Ulcerative keratitis Round cell liposarcoma Inborn error of metabolism Marfan's syndrome Monogenic diabetes Cutaneous sarcoidosis T-cell lymphoma Solitary fibrous tumour Colorectal cancer stage III Cardiac amyloidosis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Institut Paoli-Calmettes Cancer Centre

Institut Paoli-Calmettes Cancer Centre

2io Bfeopdqtj Dj Stobah Mavlutlbstw Bf 1rfa Mbkxlcjkji 1jgbia Fmuoly

Want to learn more about this study or check if you can participate? Contact us.

  • Phase I/II Study of ubamatamab plus drug combination in patients with ovarian cancer who have poor response to first‑line chemotherapy

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • Ovarian cancer
    Investigated Drugs:
    • Filgrastim
    • Bevacizumab
    • Carboplatin
    France

  • Evaluating venetoclax with drug combination in relapsed/refractory T‑cell acute lymphoblastic leukemia patients

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • T-cell type acute leukaemia
    Investigated Drugs:
    • Tofacitinib
    • Azacitidine
    • Everolimus
    Czechia France Germany The Netherlands Spain

  • Phase I/II study of DJI136 with drug combination in adult patients with extensive-stage small cell lung cancer

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • Neoplasm malignant
    • Small cell lung cancer extensive stage
    Investigated Drugs:
    • Bendamustine Hydrochloride
    • Cyclophosphamide
    • Fludarabine Phosphate
    France Spain

  • Cemsidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma

    Not yet recruiting

    2 1 1
    France Italy Poland Spain

  • Prifetrastat (PF-07248144) Plus Fulvestrant in Adults With Advanced HR+/HER2- Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitor Treatment

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • Hormone receptor positive HER2 negative breast cancer
    • Breast cancer
    • Breast cancer metastatic
    Investigated Drugs:
    • 2-METHOXY-N-{4-METHOXY-6-[(1H-PYRAZOL-1-YL)METHYL]-1,2-BENZOXAZOL-3-YL}BENZENE-1-SULFONAMIDE
    • Fulvestrant
    France

  • DB-1311 in Combination with BNT327 or DB-1305 for Patients with Advanced or Metastatic Solid Tumors

    Not yet recruiting

    2 1 1
    Investigated Diseases:
    • Squamous cell carcinoma of head and neck
    • Malignant melanoma
    • Cervix carcinoma
    Investigated Drugs:
    • HUMANISED IGG1 MONOCLONAL ANTIBODY AGAINST TROP2 CONJUGATED TO N-((7S,15S)-7-BENZYL-17-(((1S,9S)-9-ETHYL-5-FLUORO-9-HYDROXY-4-METHYL-10,13-DIOXO-2,3,9,10,13,15-HEXAHYDRO-1H,12H-BENZO[DE]PYRANO[3′,4′:6,7] INDOLIZINO[1,2-B]QUINOLIN-1-YL)AMINO)-15-METHYL-2,5,8,11,17-PENTAOXO-14-OXA-3,6,9,12-TETRAAZAHEPTADECYL)-6-(2,5-DIOXO-2,5-DIHYDRO-1H-PYRROL-1-YL)HEXANAMIDE
    • BNT327
    France Germany Italy Poland Spain

  • A study to evaluate the safety and effectiveness of nivolumab and imiquimod in adults with vulvar squamous cell carcinoma

    Not yet recruiting

    1 1 1 1
    Investigated Drugs:
    • Imiquimod
    • Nivolumab
    France

  • Study evaluating the omission of exemestane, letrozole, anastrozole, and tamoxifen in postmenopausal women with low-risk early breast cancer.

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • Hormone receptor positive HER2 negative breast cancer
    Investigated Drugs:
    • Anastrozole
    • Exemestane
    • Letrozole
    France

  • Carboplatin‑based drug combination for advanced non‑small cell lung cancer patients with interstitial lung disease

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • Interstitial lung disease
    • Non-small cell lung cancer stage IIIB
    • Non-small cell lung cancer stage IV
    Investigated Drugs:
    • Bevacizumab
    • Carboplatin
    • Gemcitabine
    France

  • A study to evaluate the safety and effectiveness of petosemtamab and pembrolizumab in adults with non-small cell lung cancer

    Not yet recruiting

    2 1 1 1
    Investigated Drugs:
    • Petosemtamab
    • Pembrolizumab
    Belgium France Italy The Netherlands Poland Spain
Previous Page
1 … 18 19 20 21 22 … 42
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!